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Abstract
Background: Cell transplantation is likely to become an important therapeutic tool for the
treatment of various traumatic and ischemic injuries to the central nervous system (CNS).
However, in many pre-clinical cell therapy studies, reporter gene-assisted imaging of cellular
implants in the CNS and potential reporter gene and/or cell-based immunogenicity, still remain
challenging research topics.
Results:  In this study, we performed cell implantation experiments in the CNS of
immunocompetent mice using autologous (syngeneic) luciferase-expressing bone marrow-derived
stromal cells (BMSC-Luc) cultured from ROSA26-L-S-L-Luciferase transgenic mice, and BMSC-Luc
genetically modified using a lentivirus encoding the enhanced green fluorescence protein (eGFP)
and the puromycin resistance gene (Pac) (BMSC-Luc/eGFP/Pac). Both reporter gene-modified
BMSC populations displayed high engraftment capacity in the CNS of immunocompetent mice,
despite potential immunogenicity of introduced reporter proteins, as demonstrated by real-time
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bioluminescence imaging (BLI) and histological analysis at different time-points post-implantation.
In contrast, both BMSC-Luc and BMSC-Luc/eGFP/Pac did not survive upon intramuscular cell
implantation, as demonstrated by real-time BLI at different time-points post-implantation. In
addition, ELISPOT analysis demonstrated the induction of IFN-γ-producing CD8+ T-cells upon
intramuscular cell implantation, but not upon intracerebral cell implantation, indicating that BMSC-
Luc and BMSC-Luc/eGFP/Pac are immune-tolerated in the CNS. However, in our experimental
transplantation model, results also indicated that reporter gene-specific immune-reactive T-cell
responses were not the main contributors to the immunological rejection of BMSC-Luc or BMSC-
Luc/eGFP/Pac upon intramuscular cell implantation.
Conclusion: We here demonstrate that reporter gene-modified BMSC derived from ROSA26-L-
S-L-Luciferase transgenic mice are immune-tolerated upon implantation in the CNS of syngeneic
immunocompetent mice, providing a research model for studying survival and localisation of
autologous BMSC implants in the CNS by real-time BLI and/or histological analysis in the absence
of immunosuppressive therapy.
Background
Cell transplantation is likely to become an important
therapeutic tool for the treatment of various traumatic
and ischemic injuries to the central nervous system
(CNS). While injuries to the CNS have been shown to trig-
ger neurogenesis from resident neural stem cells, these
endogenous self-repair mechanisms are insufficient to
induce full functional recovery [1,2]. Therefore, it is clear
that additional therapies, like cell transplantation, might
be needed to further enhance restoration of brain func-
tion following primary (e.g. impact, stroke) and second-
ary (e.g. inflammation) injury to the CNS. Although many
studies aim to replace necrotic or dysfunctional neural tis-
sue directly by implantation of stem cells, only modest
functional recovery following injury has been observed
until now [3-5]. A more realistic aim for stem cell therapy
to restore injuries to the CNS might be the implantation
of genetically modified stem cell populations in order to
produce neurotrophic factors (like BDNF, NT3 or GDNF),
with the potential to enhance survival of existing neurons
and endogenous neuroregeneration [6,7]. This approach
is currently well-described by several research groups
including ours [8-11]. For these studies, most ideally one
should be able to non-invasively visualise and localise
stem cell implants in the brain of living animals at differ-
ent time-points. For this purpose, both bioluminescence
imaging (BLI) and magnetic resonance imaging (MRI)
have been proposed as suitable non-invasive methodolo-
gies for the follow-up of cell implants in the CNS of
rodents [12-15]. While images created by MRI have a high
spatial resolution, cells need to be loaded with contrast
agents, like super paramagnetic iron oxides (SPIO), which
might display some toxicity towards the implanted cells
and surrounding tissue. Another disadvantage of these
contrast agents is leakage out of necrotic cells and uptake
by endogenous cells, which might result in false identifi-
cation of cell implant survival and localisation. In con-
trast, for generating images by BLI, cell implants need to
express the luciferase reporter protein, which, following
administration of the substrate luciferin, can produce
light through an ATP-dependent enzymatic oxidation of
luciferin. Therefore, despite the lower special resolution
than MRI, BLI visualises only viable cell implants, which
makes BLI one of the most valuable research techniques in
order to monitor survival of cell implants non-invasively.
One potential drawback of BLI is the need for genetic
modification of cell populations with the Luciferase
reporter gene. While it has been clearly documented that
the enhanced green fluorescent protein (eGFP), which is
currently the main reporter gene for histological analysis
of cell implants, is a strong immunogenic antigen and
requires the need for immune suppressive therapy during
cell implantation experiments in non-CNS tissues, it is at
the moment rather unclear whether the eGFP or luciferase
reporter proteins are tolerated by the immune system fol-
lowing cell implantation in the CNS of immune compe-
tent animals [16-19].
Methods
Animals
Homozygous ROSA26-L-S-L-Luciferase transgenic mice
(FVB background) were obtained via Jackson Laboratories
(strain 005125) and further bred in the specific pathogen
free animal facility of the University of Antwerp [20]. Male
offspring (n = 90) were used for bone marrow-derived stro-
mal cell (BMSC) culture, cell implantation experiments
and/or ELISPOT analysis. For all experiments, mice were
kept in normal day-night cycle (12/12) with free access to
food and water. All experimental procedures were
approved by the Ethics Committee for Animal Experiments
of the University of Antwerp (approval no. 2006/36).
Establishment and maintenance of primary BMSC cultures
BMSC were cultured from male ROSA26-L-S-L-Luciferase
transgenic mice following a protocol previously described
by Peister et al. [21]. Briefly, bone marrow was flushedBMC Biotechnology 2009, 9:1 http://www.biomedcentral.com/1472-6750/9/1
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from tibia and femurs of 3-week old ROSA26-L-S-L-Luci-
ferase mice. Next, harvested bone marrow was washed
twice with phosphate-buffered saline (PBS) and the total
cell population obtained was plated in a T75 culture flask
(one flask per mouse) in 20 ml 'complete isolation
medium' (CIM), consisting of RPMI-1640 medium (Invit-
rogen) supplemented with 8% horse serum (HS, Invitro-
gen), 8% fetal calf serum (FCS, Hyclone), 100 U/ml
penicillin (Invitrogen), 100 mg/ml streptomycin (Invitro-
gen), and 1.25 mg/ml amphotericin B (Invitrogen). Fol-
lowing 24 hours of culture, non-adherent cells were
removed and 20 ml fresh CIM was added to the cultures.
For a period of two weeks, CIM was replaced every 3 to 4
days. Next, cultured cells were harvested using trypsin-
EDTA (Invitrogen) treatment and replated in a new T75
culture flask in 20 ml CIM. Stromal cell outgrowth in this
culture was termed passage 1 and further expanded in
'complete expansion medium' (CEM), consisting of Iscove
modified Dulbecco's medium (IMDM, Cambrex) supple-
mented with 8% FCS, 8% HS, 100 U/ml penicillin, 100
mg/ml streptomycin and 1.25 mg/ml amphotericin B. For
routine cell culture, BMSC cultures were split 1:3 every 5 to
7 days. In addition, clonal cultures of luciferase-expressing
stromal cells were obtained by limiting dilution.
Flow cytometry
Immunophenotyping of BMSC cultures derived from
ROSA26-L-S-L-Luciferase transgenic mice was performed
using the following monoclonal antibodies: fluorescein-
isothiocyanate (FITC)-labelled anti-mouse CD31 (eBio-
science, 11/0311-82), FITC-labelled anti-mouse CD106
(eBioscience, 11/1081-82), FITC-labelled anti-mouse
CD117 (eBioscience, 11/1171-82), FITC-labelled anti-
mouse Sca-1 (eBioscience, 11/5981-82), FITC-labelled
anti-mouse MHC-I (Becton Dickinson, 5553570), phyco-
erythrin (PE)-labeled anti-mouse CD45 (Becton Dickin-
son, 553081), and PE-labelled anti-mouse MHC-II
(eBioscience, 12/5321/82). Immunostaining for A2B5
was performed using an unconjugated mouse-anti-mouse
A2B5 monoclonal antibody (Chemicon, MAB312R) fol-
lowed by staining with PE-labelled rat-anti-mouse sec-
ondary antibody (Jackson Immunoresearch, 115-116-
075). Before staining, harvested cells were washed twice
with PBS supplemented with 1% FCS (designated as
PBS*) and resuspended in PBS* at a concentration of 5 ×
105 cells/ml. For antibody staining, 1 μg of antibody was
added to 100 μl of cell suspension for 30 min at 4°C. Fol-
lowing incubation, cells were washed once with PBS*,
resuspended in 1 mL PBS*, and analysed using an Epics
XL-MCL analytical flow cytometer (Beckman Coulter).
For determination of eGFP transgene expression, har-
vested eGFP mRNA-electroporated or lentivirus-trans-
duced BMSC cultures were washed once with PBS,
resuspended in PBS and directly analysed using an Epics
XL-MCL analytical flow cytometer. Cell viability was
assessed through addition of GelRed (1× final concentra-
tion, Biotum) to the cell suspension immediately before
flow cytometric analysis. At least 10,000 cells per sample
were analysed per sample and flow cytometry data were
analysed using FlowJo software.
Messenger RNA electroporation
Messenger (m)RNA encoding the enhanced green fluores-
cent protein (eGFP) and the Cre recombinase protein was
prepared as described previously [22,23]. Prior to electro-
poration of BMSC populations, cells were washed twice
with serum-free OptiMem medium (Invitrogen) and
resuspended at a final concentration of 5–10 × 106 cells/
ml in serum-free OptiMem medium. Subsequently, 200
μl of the cell suspension was mixed with 20 μg of mRNA
and electroporated in a 4 mm electroporation cuvette at
300V and 150 μF using a Gene Pulser Xcell electropora-
tion device (Bio-Rad). After electroporation, fresh com-
plete medium was added to the cell suspension and cells
were further cultured as described above.
In vitro bioluminescence assay
Luciferase activity in cultured BMSC, BMSC-Luc and
BMSC-Luc/eGFP/Pac cell populations (1 × 105 cells per
assay) was measured using the commercial Bright-Glo
luciferase assay system (Promega), according to the man-
ufacturer's instructions.
Lentiviral construction
Construction of the pCHMWS-eGFP-IRES-Pac vector was
performed in two consecutive steps using standard clon-
ing techniques. First, the puromycin resistance gene (Pac)
was inserted downstream of an IRES element and the
resulting IRES-Pac clone was amplified by PCR and
cloned after the eGFP in the pCHMWS-eGFP vector [24].
Lentiviral transduction
Lentiviral vector production was performed as described
earlier by Geraerts et al., with minor modifications [25].
Filtered vector particles were concentrated using Vivaspin
15 columns (Vivascience, Hannover, Germany), aliq-
uoted and stored at -80°C. For transduction experiments,
cells were seeded in a 24-well plate at 50,000 cells per
well. The next day, cells were transduced with vector
expressing the eGFP-IRES-Pac cassette (2.86 105pg p24/
well) in CEM medium. After 48 hrs of incubation, the vec-
tors were washed from the cells and medium was
replaced. Cells were subcultured at least 4 times and trans-
duction efficiency was determined by flow cytometry. In
addition, a clonal line was obtained by limiting dilution
for use in further cell implantation experiments.
Cell preparation for implantation experiments
Following harvesting of BMSC-Luc and BMSC-Luc/eGFP/
Pac cell populations via trypsin/EDTA treatment, cells
were washed twice with PBS. Next, cells (mean viability of
cell populations was 90–95%) were resuspended at a con-BMC Biotechnology 2009, 9:1 http://www.biomedcentral.com/1472-6750/9/1
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centration of 100 × 106 cells/mL in PBS for intracerebral
cell implantation or at a concentration of 5 × 106 cells/mL
in PBS for intramuscular cell implantation. Cell prepara-
tions were kept on ice until intracerebral cell implanta-
tion.
Cell transplantation experiments
For cell implantation in the CNS, mice were anaesthetized
by an intraperitoneal injection of a ketamin (80 mg/kg) +
xylazin (16 mg/kg) mixture and placed in a stereotactic
frame. Next, a midline scalp incision was made and a hole
was drilled in the skull using a dental drill burr at an equal
distance between RCS and lambda and at 2 mm on the
right side of the midline. Thereafter, an automatic micro-
injector pump (kdScientific) with a 10 μl Hamilton
Syringe was positioned above the exposed dura. A 30-
gauge needle (Hamilton), attached to the syringe, was
stereotactically placed through the intact dura to a depth
of 2 mm. After 2 minutes of pressure equilibration, 2 ×
105 BMSC-Luc or BMSC-Luc/eGFP/Pac in 2 μl PBS were
injected at 0.7 μl/min. The needle was retracted after
another 3 minutes to allow pressure equilibration and to
prevent backflow of the injected cell suspension. Next, the
skin was sutured, a 0.9% NaCl solution was administered
subcutaneously in order to prevent dehydration and mice
were placed under a heating lamp to recover. For intra-
muscular cell injection, mice were anaesthetized in an
induction chamber using an isoflurane (3%) + N2 (1 L/
min) + O2 (0,5 L/min) gas mixture. Directly thereafter, 5
× 105 BMSC-Luc or BMSC-Luc/eGFP/Pac in 100 μl PBS
were injected in the right pelvic limb muscles.
In vivo bioluminescence imaging
At different time points between day 1 and week 4 after
cell implantation, mice were analysed by real-time in vivo
bioluminescence imaging (BLI) in order to determine the
presence or absence of viable cell implants in the CNS. For
this, mice were anaesthetized by intraperitoneal injection
of a ketamin (80 mg/kg) + xylazin (16 mg/kg) mixture,
followed by an intraperitoneal (brain BLI) or intravenous
(muscle BLI) injection of D-luciferin (150 mg/kg body
weight dissolved in PBS, Synchem). Immediately after
luciferin administration, mice were imaged for 20 min-
utes using an in vivo real-time φ-imager system (Biospace).
At the end of every acquisition a photographic image was
obtained. The data were analysed with Photovision soft-
ware, which superimposes the bioluminescence signal on
the photographic image. The most intense biolumines-
cence signal detected is shown in red, while the weakest
signal is shown in blue.
Brain dissection for histological analysis
At week 1 or week 3 post-implantation, mice were deeply
anaesthetized in an induction chamber by inhalation of
an isofluorane (4%), oxygen (0,5 L/min) and nitrogen (1
L/min) mixture for 2 minutes, followed by cervical dislo-
cation. Whole brains were surgically removed and fixed in
4% paraformaldehyde for 2 hours.
Histological analysis
Fixed brains were dehydrated in sucrose gradients (5%,
10% and 20%), frozen in liquid nitrogen and stored at -
80°C until further processing. Consecutive 10 μm-thick
cryosections were cut using a Microm HM5000 cryostat
and stained with haematoxylin-eosin (HE) to locate the
transplantation site. Further immunohistochemical anal-
ysis was performed using a biotin-labeled anti-mouse Sca-
1 antibody (eBioscience 13-5981-85) for BMSC identifi-
cation, and a biotin-labeled anti-mouse CD11b antibody
(eBioscience 13-0112-85) for detection of activated
microglia at the site of cell implantation. In brief, slides
were rinsed with a washing buffer and endogenous perox-
idase was blocked following 30 min incubation with
methanol containing 1% hydrogen peroxide. Next, slides
were washed with water and washing buffer, followed by
incubation with normal rat serum (Jackson Immuno
Research 012-000-120) for 1 hour at room temperature.
Subsequently, slides were incubated for 3 hours with the
biotin-labeled primary antibody at room temperature.
Following this, slides were rinsed with washing buffer,
and incubated for 1 hour at room temperature with a
streptavidin-horse-radish-peroxidase complex (Dako
00032671). Visualization for all slides was carried out
after staining with diaminobenzidine (DAB, Dako),
according to manufacturer's instructions, and nuclei were
counterstained with Carazzi's haematoxylin. Bright-field
immunohistochemical analysis was done using an Olym-
pus Bx41 microscope equipped with an Olympus DP50
camera. Olympus DP Software was used for image collec-
tion.
ELISPOT analysis
A murine IFN-γ ELISPOT assay (Diaclone, 862.031.010.S)
was performed according to manufacturer's instructions.
In brief, spleens were dissected from cell-transplanted
ROSA26-L-S-L-Luciferase transgenic mice (both intramus-
cular and intracerebral) at 2 weeks post-injection. Next,
after dissociation of the spleens over a 100 μm nylon fil-
ter, mononuclear cells were enriched following a density-
based centrifugation step (Ficoll-Paque Plus, GE Health-
care). Magnetic isolation of CD8+ T-cells was done using
anti-CD8 MACS MicroBeads (Miltenyi Biotec, 130-049-
401), according to the manufacturer's instructions. Iso-
lated CD8+ T-cells (= responder cells) were plated on
ELISPOT plates at 1 × 105 cells/well in IMDM supple-
mented with 10% FBS, penicillin/streptomycin and
amphotericin B. Cells were then cultured for 16 hours
either: (i) un-stimulated, (ii) stimulated with 1 × 104
parental BMSC (= non stimulator cells), or (III) stimu-
lated with 1 × 104 BMSC-Luc or BMSC-Luc/eGFP/Pac (=
stimulator cells). All experiments were performed in
quadruplicate per mouse. The ELISPOT plates were ana-BMC Biotechnology 2009, 9:1 http://www.biomedcentral.com/1472-6750/9/1
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lysed using an AID ELISPOT Reader (Autoimmun Diag-
nostika GmbH). Data are presented as IFN-γ spot-forming
cells (SFC) per 1 × 105 CD8+ responder T-cells.
Statistical analysis
Results are expressed as mean ± standard deviation. Com-
parisons were validated using Student's t-test. A p-value <
0.01 was considered to be statistically significant.
Results
Culture and characterisation of a clonal luciferase-
expressing bone marrow-derived stromal cell line from 
ROSA26-L-S-L-Luciferase transgenic mice
ROSA26-L-S-L-Luciferase transgenic mice were originally
described as a mouse reporter strain for non-invasive
monitoring of in vivo Cre-recombination by biolumines-
cence imaging[20]. In these mice, a luciferase reporter
gene, which is preceded by a loxP-flanked neomycin
resistance gene, was integrated into the ROSA26 genomic
locus by homologous recombination (Figure 1A). In this
study, we first attempted to culture bone marrow-derived
stromal cells (BMSC) starting from bone marrow of 3-
week old ROSA26-L-S-L-Luciferase transgenic mice, as
described in detail in the Materials and Methods section.
At passage 3, when cultures became homogenous for cells
with BMSC morphology (Figure 1B, left picture), cell cul-
tures (n = 3) were analysed by flow cytometry for the pres-
ence and absence of typical membrane proteins
characteristic for defining murine BMSC [21]. Flow cyto-
metric analysis indicated that the cultured cell popula-
tions displayed uniform expression of Sca-1, V-CAM, and
MHC-I, without detectable expression of haematopoietic
(CD45, c-kit, MHC-II), endothelial (CD31) and neural
(A2B5) membrane proteins (data not shown). One paren-
tal BMSC line was then chosen ad random and used for
further experiments described in this manuscript. In order
to allow expression of the luciferase protein in BMSC
derived from ROSA26-L-S-L-Luciferase transgenic mice, a
"floxed" neomycin resistance cassette needs to be excised
by the Cre recombinase protein. We previously described
a methodology for efficient Cre-mediated excision of tar-
get sequences following electroporation of cells with mes-
senger (m)RNA encoding Cre recombinase [22,23].
Following this strategy, we first evaluated whether murine
BMSC were susceptible for mRNA-based gene transfer.
Flow cytometric analysis of BMSC electroporated with
mRNA encoding the enhanced green fluorescent protein
(eGFP) indicated efficient transgene expression in up to
80% of cells at 24 hours post-electroporation (Figure 1C,
n = 4). Next, parental BMSC were electroporated with
mRNA encoding the Cre recombinase protein in order to
activate luciferase expression. A polyclonal luciferase-
expressing BMSC line was obtained, which displayed sta-
ble expression of luciferase protein for at least 10 passages,
as demonstrated by standard in vitro luminescence assays
(Figure 1D, n = 8). Next, multiple clonal luciferase-
expressing BMSC lines were obtained by limiting dilution
and screened for high luciferase activity by standard in
vitro luminescence assay. One clonal line was chosen and
used for further characterisation and transplantation
experiments described below. This clonal luciferase-
expressing BMSC line (further named as BMSC-Luc) was
further characterised in vitro based on (1) BMSC morphol-
ogy (Figure 1B, right picture) and immune phenotype
(Figure 1E), for which no difference was observed with
parental BMSC derived from ROSA26-L-S-L-luciferase
transgenic mice, and based on (2) luciferase activity,
which was increased as compared to the described poly-
clonal luciferase-expressing BMSC cells and remained sta-
ble over at least 20 passages as demonstrated by standard
in vitro luminescence assays (Figure 1D, n = 10; and see
Additional file 1).
Survival of luciferase-expressing BMSC derived from 
ROSA26-L-S-L-Luciferase transgenic mice following 
implantation in the central nervous system of syngeneic 
immunocompetent mice
In order to investigate whether our cultured clonal BMSC-
Luc derived from ROSA26-L-S-L-luciferase transgenic
mice can survive intrinsically and/or immunologically
upon implantation into the central nervous system (CNS)
of immune competent mice, 2 × 105 cells were grafted in
the CNS of syngeneic ROSA26-L-S-L-Luciferase mice (n =
28), following procedures described in detail in the Mate-
rials and Methods section. In this experimental context,
only the luciferase protein produced by the implanted
BMSC-Luc can be seen as a potential immunogenic anti-
gen in the CNS. Next, survival of BMSC-Luc implants was
monitored by real-time in vivo bioluminescence imaging
(BLI) until day 1, week 1, week 2, week 3 or week 4 post-
implantation. Only mice showing a clear BLI signal on
day 1 post-implantation (60%), indicating successful cell
implantation in the CNS for BLI imaging, were included
for long-term follow-up by BLI. For these mice, a clear BLI
signal was detected in 17/17 mice analysed at week 1 post-
implantation, in 17/17 mice analysed at week 2 post-
implantation, in 6/6 mice analysed at week 3 post-
implantation, and in 5/5 mice analysed at week 4 post-
implantation. These results suggest both intrinsic and
immunological survival of BMSC-Luc cell implants in the
CNS of syngeneic immunocompetent mice (Figure 2A),
despite potential immunogenicity of the luciferase trans-
gene. In addition, at different time-points post-implanta-
tion, randomly chosen animals (both from BLI and non-
BLI-group) were sacrificed and dissected brains were ana-
lysed for cell graft survival and inflammatory responses.
As shown in Figure 2B, cell implants are clearly visible at
week 1 and week 3 post-implantation following haema-
toxylin-eosin (HE) staining of brain slices. These results
also validate the observed in vivo BLI results described
above. Moreover, immunohistochemical staining for Sca-
1 clearly identifies the BMSC origin of the cell implantsBMC Biotechnology 2009, 9:1 http://www.biomedcentral.com/1472-6750/9/1
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Culture and characterisation of a clonal luciferase-expressing bone marrow-derived stromal cell line from ROSA26-L-S-L-Luci- ferase transgenic mice Figure 1
Culture and characterisation of a clonal luciferase-expressing bone marrow-derived stromal cell line from 
ROSA26-L-S-L-Luciferase transgenic mice. (A) Molecular organisation of the ROSA26 locus in ROSA26-L-S-L-Luciferase 
transgenic mice. (B) Representative pictures of cultured bone marrow-derived stromal cells (BMSC) taken under phase con-
trast microscopy. Left: unmodified parental BMSC derived from ROSA26-L-S-L-Luciferase transgenic mice (BMSC parental). 
Right: clonal luciferase-expressing BMSC derived from ROSA26-L-S-L-Luciferase transgenic mice (BMSC-Luc clonal). (C) 
Parental BMSC derived from ROSA26-L-S-L-Luciferase transgenic mice were non-electroporated (NO EP, upper dot plot) or 
electroporated with eGFP mRNA (EP eGFP, lower dot plot), and were analyzed by flow cytometry for eGFP fluorescence (x-
axis) versus viability (GelRed-staining, y-axis) after 24 hours of culture. The percentage indicated in the lower left quadrant is 
the number of viable eGFP-negative cells. The percentage indicated in the lower right quadrant is the number of viable eGFP-
positive cells. The percentages indicated in the upper left and right quadrant are numbers of non-viable cells. Representative 
dot plots are shown. (D) In vitro luminescence assay on parental BMSC (BMSC parental), on Cre-recombined polyclonal luci-
ferase-expressing BMSC (BMSC-Luc polyclonal), and on Cre-recombined clonal luciferase-expressing BMSC (BMSC-Luc 
clonal), all derived from ROSA26-L-S-L-Luciferase transgenic mice. (E) Representative flow cytometric analysis showing 
expression pattern of membrane proteins on clonal BMSC-Luc derived from ROSA26-L-S-L-Luciferase transgenic mice (i.e. 
expression of Sca-1, V-CAM and MHC-I, but no expression of MHC-II, c-kit, CD45, CD31 and A2B5). Open histograms: con-
trol. Filled histograms: specific antibody staining.BMC Biotechnology 2009, 9:1 http://www.biomedcentral.com/1472-6750/9/1
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observed (Figure 2B). In addition, we investigated
whether the implantation of autologous (syngeneic)
BMSC-Luc in the CNS of mice triggers inflammatory
responses. For this, brain sections were stained for the
presence of CD11b+ activated microglia in the surround-
ings of grafted BMSC-Luc (Figure 2B). Results indicate
that at an early time point post-implantation (week 1)
microglial activation does occur, however, this inflamma-
tory response is only temporary as the presence of these
CD11b+ activated microglial cells is highly diminished at
a later time point post-implantation (week 3). In contrast
to the above-described results, intramuscular BMSC-Luc
cell implants did not survive beyond week 1 post-implan-
tation as demonstrated by in vivo BLI (Figure 2C). For the
latter, a clear BLI signal was detected in 8/9 mice analysed
at day 1 post-implantation, in 4/7 mice analysed at week
1 post-implantation, in 0/7 mice analysed at week 2 post-
implantation and in 0/7 mice analysed at week 3 post-
implantation.
Survival of BMSC genetically modified with multiple 
reporter genes following implantation in the central 
nervous system of syngeneic immunocompetent mice
In order to investigate whether the immunological sur-
vival of BMSC-Luc in the CNS of syngeneic immunocom-
petent mice was due to low immunogenicity of the
luciferase protein in the CNS, we introduced additional
xenogeneic reporter genes into our cultured BMSC-Luc.
For this, BMSC-Luc were transduced with a lentivirus
encoding the enhanced green fluorescence protein (eGFP)
and the puromycin resistance gene (Pac). Following puro-
mycin selection and single clone selection, a clonal Luci-
ferase-, EGFP- and Pac-expressing BMSC line was
obtained (further named as BMSC-Luc/eGFP/Pac). Flow-
cytometric analysis of BMSC-Luc/eGFP/Pac demonstated
eGFP transgene expression in > 95% of the cells (Figure
3A), which remained stable in culture for at least 15 pas-
sages. In addition, phenotypical properties (data not
shown) and luciferase activity (Figure 3B, n = 3) were not
influenced following lentiviral-transduction of BMSC-
Luc. Next, in order to investigate the in vivo immunologi-
cal survival of BMSC genetically-modified with multiple
reporter genes in immunocompetent mice, 2 × 105 BMSC-
Luc/eGFP/Pac were implanted in the CNS of syngeneic
ROSA26-L-S-L-luciferase transgenic mice (n = 8). Survival
of grafted BMSC-Luc/eGFP/Pac was then monitored by in
vivo BLI on day 1, week 1 and week 2 post-implantation
(Figure 3C). A clear BLI signal was observed in 8/8 mice
analysed at day 1 post-implantation, in 6/8 mice analysed
at week 1 post-implantation and in 6/6 mice analysed at
week 2 post-implantation. In addition, histological analy-
sis (Figure 3E, n = 2) at week 2 post-implantation con-
firmed: (I) the presence of eGFP-expressing BMSC-Luc/
eGFP/Pac implants, and (II) a limited number of activated
CD11b+ microglia surrounding BMSC-Luc/eGFP/Pac
implants, indicating survival of BMSC-Luc/eGFP/Pac cell
implants in the CNS of syngeneic immunocompetent
mice. In contrast, intramuscular BMSC-Luc/eGFP/Pac
implants did not survive beyond week 1 post-implanta-
tion (Figure 3D) as demonstrated by in vivo BLI. In these
experiments, a clear BLI signal was detected in 4/4 mice at
day 1 post-implantation, in 3/4 mice at week 1 post-
implantation and in 0/4 mice at week 2 post-implanta-
tion.
Induction of BMSC-specific CD8+ T-cell responses 
following intramuscular, but not intracerebral, cell 
implantation in syngeneic immunocompetent mice
In order to investigate whether the non-survival of intra-
muscular BMSC-Luc and BMSC-Luc/eGFP/Pac cell
implants was mediated by the host's immune system, we
evaluated the presence of reporter gene-specific interferon
(IFN)-γ-producing CD8+ T-cells by ELISPOT analysis. For
this, spleen CD8+ T-cells were isolated from control mice
and from BMSC-Luc or BMSC-Luc/eGFP/Pac cell
implanted mice (both intramuscular and intracerebral
implants) at week 2 post-implantation. Then, isolated
CD8+ T-cells were un-stimulated, re-stimulated with
parental BMSC, or re-stimulated with BMSC-Luc or
BMSC-Luc/eGFP/Pac in an IFN-γ ELISPOT assay (Figure
4). Interestingly, no significant number of IFN-γ-produc-
ing CD8+ T-cells directed against BMSC-Luc (figure 4A;
BMSC-Luc re-stimulation – control mice (n = 4) versus
intracerebral BMSC-Luc graft (n = 6) – p = 0.07) or BMSC-
Luc/eGFP/Pac (figure 4B; BMSC-Luc/eGFP/Pac re-stimu-
lation – control mice (n = 4) versus intracerebral BMSC-
Luc/eGFP/Pac graft (n = 6) – p = 0.32) cell implants was
detected upon intracerebral cell implantation. However, a
large number of reactive IFN-γ-producing CD8+ T-cells
directed against BMSC-Luc (figure 4A; BMSC-Luc re-stim-
ulation – control mice versus intramuscular BMSC-Luc
graft (n = 5) – p < 0.001) or BMSC-Luc/eGFP/Pac (figure
4B; BMSC-Luc/eGFP/Pac re-stimulation – control mice
versus intramuscular BMSC-Luc/eGFP/Pac graft (n = 5) –
p < 0.001) was observed upon intramuscular cell implan-
tation. These results demonstrate that BMSC-Luc and
BMSC-Luc/eGFP/Pac specific IFN-γ-producing T-cells are
efficiently induced upon intramuscular cell implantation,
but not upon intracerebral cell implantation, indicating
potential immunogenicity of our reporter gene-modified
BMSC for the peripheral immune system, but not for the
CNS immune system. In an attempt to demonstrate that
the observed IFN-γ-producing T-cells were specific for
Luciferase, eGFP or Pac, isolated CD8+ T-cells were also
re-stimulated with parental BMSC. Surprisingly, CD8+ T-
cells isolated from intramuscular BMSC-Luc or BMSC-
Luc/eGFP/Pac cell implanted mice were equally reactive
against parental non-modified BMSC (figure 4A; intra-
muscular BMSC-Luc graft – BMSC re-stimulation versus
BMSC-Luc re-stimulation – p = 0.06) (figure 4B; intramus-
cular BMSC-Luc/eGFP/Pac graft – BMSC re-stimulation
versus BMSC-Luc/eGFP/Pac re-stimulation – p = 0.26)BMC Biotechnology 2009, 9:1 http://www.biomedcentral.com/1472-6750/9/1
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Survival of luciferase-expressing BMSC derived from ROSA26-L-S-L-Luciferase transgenic mice following implantation in the  central nervous system of syngeneic immunocompetent mice Figure 2
Survival of luciferase-expressing BMSC derived from ROSA26-L-S-L-Luciferase transgenic mice following 
implantation in the central nervous system of syngeneic immunocompetent mice. (A) Representative time course 
for in vivo bioluminescence imaging of clonal BMSC-Luc derived from ROSA26-L-S-L-Luciferase transgenic mice following 
implantation in the central nervous system of syngeneic immunocompetent mice. (B) Representative histological analysis of 
clonal BMSC-Luc grafts in the central nervous system of syngeneic immunocompetent mice. Week 1 post-implantation: Upper 
pictures, haematoxylin-eosin (HE) staining indicating localisation and general appearance of the implantation site. Lower left 
picture, Sca-1 staining indicating the BMSC origin of the observed cell graft. Lower right picture, CD11b staining indicating the 
presence of activated microglia surrounding the observed cell graft. Week 3 post-implantation: Upper pictures, HE staining 
indicating localisation and general appearance of the implantation site. Lower left picture, Sca-1 staining indicating the BMSC 
origin of the observed cell graft. Lower right picture, CD11b staining indicating the absence of activated microglia surrounding 
the observed cell graft. All slides were examined using a conventional bright field microscope and digital pictures were taken 
under magnification as indicated by the scale bars. (C) Representative time course for in vivo bioluminescence imaging of clonal 
BMSC-Luc derived from ROSA26-L-S-L-Luciferase transgenic mice following intramuscular implantation in syngeneic immuno-
competent mice.BMC Biotechnology 2009, 9:1 http://www.biomedcentral.com/1472-6750/9/1
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The latter indicates that the non-survival of intramuscular
BMSC-Luc or BMSC-Luc/eGFP/Pac cell implants – in our
experimental model – is not mediated by reporter gene-
specific T-cells, although it is unclear at the moment
which antigens were responsible for initiating T-cell acti-
vation against our cultured BMSC.
Discussion
In many pre-clinical cell therapy studies, reporter gene-
assisted imaging of cellular implants in the CNS and
potential reporter gene and/or cell-based immunogenic-
ity, still remain challenging research topics. In this study,
we first aimed to investigate whether luciferase-expressing
bone marrow-derived stromal cells (BMSC), derived from
ROSA26-L-S-L-Luciferase transgenic mice, can be
implanted and survive in the CNS of immunocompetent
syngeneic luciferase-negative ROSA26-L-S-L-Luciferase
transgenic mice, despite the potential immunogenicity of
the luciferase protein [19,20]. The choice of ROSA26-L-S-
L-Luciferase transgenic mice for performing these experi-
ments has two reasons. First, we assumed that the epige-
netic stability of luciferase expression would be much
higher when cell populations were derived from a well-
characterised luciferase-expressing transgenic mouse
strain, as compared to ex vivo transgenesis using plasmid
DNA or viruses [11,26]. Second, Cre recombination in
cells derived from ROSA26-L-S-L-Luciferase transgenic
mice allows removal of a floxed neomycin resistance gene
(Figure 1A), resulting in luciferase protein expression
without additional selection markers. Following this strat-
egy, i.e. derivation of cell populations from ROSA26-L-S-
L-Luciferase transgenic mice followed by Cre-recombina-
tion in order to activate luciferase expression, autologous
transplantation experiments can be performed in syn-
geneic luciferase-negative ROSA26-L-S-L-Luciferase trans-
genic mice with only the luciferase protein as potential
immunogen. In this context, we derived BMSC cultures
from ROSA26-L-S-L-Luciferase transgenic mice and char-
acterised these BMSC populations as described by Peister
et al [21]. Immunophenotypic analysis (Figure 1E) clearly
demonstrated the uniform expression of mesenchymal
markers (Sca-1 and V-CAM) without detectable expres-
sion of endothelial (CD31), haematopoietic (c-kit, CD45
and MHC-II) or neural (A2B5) markers.
Next, in order to allow expression of the luciferase protein
in BMSC derived from ROSA26-L-S-L-Luciferase trans-
genic mice, a floxed neomycine resistance cassette needs
to be excised by the Cre recombinase protein. We previ-
ously described a non-viral non-DNA gene transfer meth-
odology for highly efficient protein expression in a variety
of cell types, including human BMSC, based on electropo-
ration of messenger RNA [27-30]. In this study, following
these previous reports, we also describe for the first time
highly efficient mRNA-based gene transfer in murine
BMSC using the enhanced green fluorescent protein
(eGFP) reporter gene (Figure 1C). The latter is of impor-
tance when transient protein expression is desired and
introduction of DNA sequences (either by plasmid DNA
or viruses) should be avoided [31,32]. Next, our cultured
BMSC populations were electroporated with mRNA
encoding the Cre recombinase protein, following previ-
ously described procedures [22,23]. Although luciferase
expression was induced (Figure 1D, BMSC-Luc polyclo-
nal), the culture of a clonal luciferase-expressing BMSC
was necessary in order to obtain a pure population
expressing high levels of the luciferase protein (Figure 1D,
BMSC-Luc clonal). The fact that recombination efficiency
was rather low in cultured BMSC following electropora-
tion with Cre recombinase mRNA, despite the observa-
tion that electroporation with EGFP mRNA resulted in
high levels of transfection efficiency, can be ascribed to
variations in Cre recombinase activity in different cell
types (published and unpublished data) [22,23].
In our transplantation model, i.e. autologous implanta-
tion of BMSC-luc derived from ROSA26-L-S-L-Luciferase
transgenic mice in the CNS of syngeneic luciferase-nega-
tive ROSA26-L-S-L-Luciferase transgenic mice, we rou-
tinely transplant 2 × 105 cells in order to obtain a clear
signal for in vivo bioluminescence imaging (BLI). Further
experiments revealed a minimum of 5 × 104 cells to be
required for obtaining a minimum signal above back-
ground (data not shown). However, this detection limit
might be different when using BMSC derived from
another luciferase-expressing transgenic mouse or follow-
ing lentiviral transduction with the luciferase reporter pro-
tein. Following cell transplantation in this model, we did
not observe immune-mediated rejection of BMSC-Luc
implants in the CNS during a follow-up period of 3-4
weeks by real-time BLI (Figure 2A), while intramuscular
BMSC-Luc implants did not survive during the same fol-
low-up period (Figure 2C). Also, when the same BMSC
population was implanted in the CNS of immunocompe-
tent allogeneic C57/BL6 mice (see Additional file 2) or
when C57/BL6 BMSC were implanted in the CNS of
immunocompetent ROSA26-L-S-L-Luciferase transgenic
mice (data not shown), no survival of grafted cells was
observed during the same follow-up period. These results
suggest that BMSC-Luc derived from ROSA26-L-S-L-Luci-
ferase transgenic mice can indeed survive immunologi-
cally in the CNS of immunocompetent luciferase-negative
ROSA26-L-S-L-Luciferase transgenic mice, despite the
potential immunogenicity of the luciferase protein. In
addition, during the observation period of 3-4 weeks, we
did not observe a significant increase of in vivo biolumi-
nescence signal over time. The latter, although further
investigation will be needed (e.g. quantitative analysis),
might become a tool to exclude tumour formation follow-
ing cell implantation [12].BMC Biotechnology 2009, 9:1 http://www.biomedcentral.com/1472-6750/9/1
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Survival of BMSC genetically modified with multiple reporter genes following implantation in the central nervous system of syn- geneic immunocompetent mice Figure 3
Survival of BMSC genetically modified with multiple reporter genes following implantation in the central nerv-
ous system of syngeneic immunocompetent mice. (A) Histogram overlay showing a representative flow cytometric 
analysis of eGFP expression by BMSC expressing the luciferase-, eGFP- and puromycin resistance genes (BMSC-Luc/eGFP/Pac, 
filled histogram). Parental BMSC were used as negative control (open histogram). (B) In vitro luminescence assay on parental 
BMSC and on clonal BMSC-Luc/eGFP/Pac. (C) In vivo real time bioluminescence imaging (BLI) of clonal BMSC-Luc/eGFP/Pac 
grafts in the central nervous system (CNS) of syngeneic immunocompetent mice at week 2 post-implantation. (D) In vivo real 
time BLI of clonal BMSC-Luc/eGFP/Pac intramuscular grafts in syngeneic immunocompetent mice at week 2 post-injection. (E) 
Representative histological analysis of clonal BMSC-Luc/eGFP/Pac implants in the CNS of syngeneic immunocompetent mice at 
week 2 post-implantation. Left picture: haematoxylin-eosin (HE) staining showing general appearance of the cell implantation 
site. Middle picture: direct eGFP-fluorescence indicating the BMSC-Luc/eGFP/Pac origin of the observed cell implant. Right pic-
ture: CD11b staining indicating a limited number of microglia surrounding the observed cell graft. All slides were examined 
using a conventional bright field microscope and digital pictures were taken under magnification as indicated by the scale bars.BMC Biotechnology 2009, 9:1 http://www.biomedcentral.com/1472-6750/9/1
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Induction of BMSC-specific CD8+ T-cell responses following intramuscular, but not intracerebral, cell implantation in syngeneic  immunocompetent mice Figure 4
Induction of BMSC-specific CD8+ T-cell responses following intramuscular, but not intracerebral, cell implan-
tation in syngeneic immunocompetent mice. (A) Spleen CD8+ T-cells (1 × 105 cells/well) from non-transplanted 
ROSA26-L-S-L-Luciferase mice (control mice, n = 4) and ROSA26-L-S-L-Luciferase mice with BMSC-Luc implants, either intra-
muscularly (intramuscular BMSC-Luc graft, n = 5) or intracerebrally (intracerebral BMSC-Luc graft, n = 6), were cultured in 
quadruplet in an IFN-γ ELISPOT assay alone (unstimulated), with addition of parental BMSC (BMSC re-stimulation) or with 
addition of BMSC-Luc (BMSC-Luc re-stimulation) (1 × 104 cells/well, ratio 10:1). Data are expressed as the mean number of 
IFN-γ spot forming cells (SFC)/1 × 105 CD8+ T-cells for each experimental group. (B) Spleen CD8+ T-cells (1 × 105 cells/well) 
from non-transplanted ROSA26-L-S-L-Luciferase mice (control mice, n = 4) and ROSA26-L-S-L-Luciferase mice with BMSC-
Luc/eGFP/Pac implants, either intramuscularly (intramuscular BMSC-Luc/eGFP/Pac graft, n = 5) or intracerebrally (intracere-
bral BMSC-Luc/eGFP/Pac graft, n = 6), were cultured in quadruplet in an IFN-γ ELISPOT assay alone (unstimulated), with addi-
tion of parental BMSC (BMSC re-stimulation) or with addition of BMSC-Luc/eGFP/Pac (BMSC-Luc/eGFP/Pac re-stimulation) (1 
× 104 cells/well, ratio 10:1). Data are expressed as the mean number of IFN-γ spot forming cells (SFC)/1 × 105 CD8+ T-cells for 
each experimental group.BMC Biotechnology 2009, 9:1 http://www.biomedcentral.com/1472-6750/9/1
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In order to further investigate the tolerogenic properties of
the CNS with regard to reporter gene-modified BMSC
implants, we further genetically engineered our BMSC-
Luc cells using a lentivirus encoding eGFP and the puro-
mycin resistance gene (Figure 3A). Following transplanta-
tion of these BMSC-Luc/eGFP/Pac in the CNS of syngeneic
immunocompetent mice, a similar degree of cell survival
was observed as compared to BMSC-Luc implants (Figure
3C and 3E). Again, no cell survival was observed upon
intramuscular BMSC-Luc/eGFP/Pac implantation. These
results demonstrate that reporter gene-modified BMSC
can survive immunologicaly in the CNS of syngeneic
immunocompetent mice. Currently, we do not know why
expression of reporter proteins (in this study Luc, eGFP
and Pac), which are from an immunological point of view
a foreign antigens, are tolerated in the CNS. Several expla-
nations can be hypothesised for this: (1) some cell popu-
lations, among them BMSC, have been ascribed immune
modulatory properties [33], or (2) immune surveillance
mechanisms in the CNS are not properly activated [34],
both possibly leading to immunological acceptance of the
neo-expressed reporter proteins in the CNS. In this con-
text, we investigated whether inflammatory responses
occur following cell implantation in the CNS. Although
histological analysis of cell-implanted brains indicated
the presence of activated CD11b+ microglial cells sur-
rounding the cell graft at week 1 post-implantation, the
presence of these CNS immune cells was highly dimin-
ished by week 3 post-implantation, indicating immuno-
logical acceptance of autologous BMSC-Luc (Figure 2B) or
BMSC-Luc/eGFP/Pac (Figure 3E). However, the observed
immune tolerance of the CNS for reporter gene-modified
BMSC does not imply an absolute immune tolerance of
the CNS. In contrast, allogeneic cell implantation in the
CNS of immunocompetent mice leads to a sustained acti-
vation of microglia and rejection of cell implants by week
2–4 post-implantation (see Additional file 2).
Finally, we aimed to investigate whether the non-survival
of intramuscular BMSC-Luc and BMSC-Luc/eGFP/Pac cell
implants was mediated by the host's immune system.
Although the presence of reactive IFN-γ-producing CD8+
T-cells was clearly demonstrated following intramuscular,
but not intracerebral, BMSC-Luc and BMSC-Luc/eGFP/
Pac cell implantation (Figure 4), surprisingly these
immune reactive T-cell response were not specific for the
introduced reporter genes. Although further research will
be needed to elucidate the specificity of the induced
BMSC-specific IFN-γ-producing CD8+ T-cells, several
explanations can be hypothesised for this: (1) due to the
use of fetal calf serum and horse serum for in vitro BMSC
expansion, xenogeneic serum components (eg. glycolip-
ids) might have induced cellular immunogenicity, or (2)
cell culture induced genomic alterations might have
resulted in the expression of highly immunogenic neo-
antigens, both possibly leading to immunological rejec-
tion of our BMSC cultures following intramuscular cell
implantation.
Conclusion
While many cell transplantation studies are currently per-
formed under immunosuppressive therapy or in immune-
deficient mice, clinical applications of cell therapy will
most likely have to deal with immunocompetent patients.
In this study, we demonstrate that reporter gene-modified
BMSC derived from ROSA26-L-S-L-Luciferase transgenic
mice are immune-tolerated upon cell implantation in the
CNS of syngeneic immunocompetent mice. The proposed
research model thus provides a powerful tool for studying
survival and localisation of autologous BMSC implants in
the central nervous system of syngeneic mice by real-time
bioluminescence imaging and/or histological analysis in
the absence of immunosuppressive therapy.
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